A critical analytical aspect on analytical protocols in the pharmaceutical analysis of H1N1 antiviral agent and its active metabolite

A critical analytical aspect on analytical protocols in the pharmaceutical analysis of H1N1 antiviral agent and its active metabolite

Abstract Background Oseltamivir (OSM) was the first active oral therapeutic inhibitor approved by the Food and Drug Administration in 1999 for the clinical management of the influenza virus. It is an ester-type prodrug of OSM carboxylate in the market under the trade name Tamiflu™ capsules, i.e., os...

Full description

Bibliographic Details
Main Authors: Suraj R. Chaudhari, Vaibhavi K. Salunkhe, Shubham D. Tabade, Pragati K. Bhonde, Sarthak G. Kulkarni, Dnyaneshwar H. Maykar, Saurabh B. Ganorkar, Sanjay J, Surana, Atul A. Shirkhedkar
Format: Article
Language:English
Published: SpringerOpen 2024-08-01
Series:Future Journal of Pharmaceutical Sciences
Subjects:
Analytical protocols
Influenza virus
Neuraminidase inhibitor
Oseltamivir
Online Access:https://doi.org/10.1186/s43094-024-00666-6

Internet

https://doi.org/10.1186/s43094-024-00666-6

Similar Items